Corcept's Cure: New Partnerships and Pipeline Power
Update: 2025-10-01
Description
Corcept Therapeutics stock jumps after partnering with Curant Health to boost patient support for its Cushing's syndrome drug, Korlym, while also awaiting FDA review for relacorilant in ovarian cancer. Is this enough to diversify beyond Korlym and propel the stock back to its all-time high?
Hosted on Acast. See acast.com/privacy for more information.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
